Literature DB >> 2582709

Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4.

M J Bargetzi1, T Aoyama, F J Gonzalez, U A Meyer.   

Abstract

The metabolism of lidocaine to its major metabolite monoethylglycinexylidide (MEGX) was studied in human liver microsomes of 13 kidney transplant donors and of one patient with liver cirrhosis. Interindividual variation in metabolite formation was considerable. Biphasic kinetics indicated the involvement of at least two distinct enzymatic activities. With use of a series of antisera that recognize different human cytochrome P450 isozymes, we were able to identify an enzyme of the P450III gene family as one of two enzymes. By expressing human P450IIIA4 complementary deoxyribonucleic acid (cDNA) in HepG2 cells, we directly demonstrated lidocaine-deethylase activity for this P450 isozyme. These data suggest that P450IIIA4 is at least in part responsible for microsomal MEGX formation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2582709     DOI: 10.1038/clpt.1989.180

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  49 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Formation of porcine hepatocyte spherical multicellular aggregates (spheroids) and analysis of drug metabolic functions.

Authors:  K Nakazawa; H Mizumoto; M Kaneko; H Ijima; T Gion; M Shimada; K Shirabe; K Takenaka; K Sugimachi; K Funatsu
Journal:  Cytotechnology       Date:  1999-09       Impact factor: 2.058

3.  Indocyanine green elimination test in orthotopic liver recipients.

Authors:  T Tsubono; S Todo; N Jabbour; A Mizoe; V Warty; A J Demetris; T E Starzl
Journal:  Hepatology       Date:  1996-11       Impact factor: 17.425

Review 4.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

5.  Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.

Authors:  Rocco Orlando; Pierpaolo Piccoli; Sara De Martin; Roberto Padrini; Pietro Palatini
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

6.  Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry.

Authors:  A Bader; E Knop; K H Böker; O Crome; N Frühauf; A K Gonschior; U Christians; H Esselmann; R Pichlmayr; K F Sewing
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

7.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

8.  Lidocaine concentration in mandibular bone after subperiosteal infiltration anesthesia decreases with elevation of periosteal flap and irrigation with saline.

Authors:  Sachie Ogawa; Masahiro Watanabe; Hiroyoshi Kawaai; Hitoshi Tada; Shinya Yamazaki
Journal:  Anesth Prog       Date:  2014

9.  In vitro inhibition of midazolam and quinidine metabolism by flavonoids.

Authors:  H R Ha; J Chen; P M Leuenberger; A U Freiburghaus; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  The effect of liver disease and food on plasma MEGX concentrations.

Authors:  R Pritchard-Davies; A S Gross; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.